Avacta Group PLC (LSE:AVCT) has presented its first preclinical data on its dual payload pre|CISION® technology at the 2025 AACR-NCI-EORTC International Conference, marking a major step forward in targeted cancer treatment. The innovative approach enables the simultaneous delivery of two therapeutic payloads directly to the tumor microenvironment, offering the potential to overcome drug resistance and improve tumor control.
The company’s dual payload program features combinations such as microtubule inhibition with topoisomerase I inhibition, and DNA damage response agents paired with exatecan. Early findings from the pre|CISION® platform demonstrate strong tumor selectivity and therapeutic efficacy, underscoring its potential to transform the treatment of highly resistant cancers through precise, targeted drug delivery.
Despite the scientific progress, Avacta Group plc continues to face financial challenges, including negative profitability and elevated leverage. While technical indicators and clinical advancements provide some positive momentum, valuation pressures and funding constraints remain key headwinds.
More about Avacta Group plc
Avacta Group plc is a clinical-stage life sciences company focused on developing novel cancer therapies through its proprietary pre|CISION® drug delivery platform. The technology employs peptide drug conjugate (PDC) science to enhance the precision and safety of oncology treatments by activating drugs specifically within tumors, thereby minimizing systemic toxicity and side effects.
Leave a Reply